| Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? CM Fares, EM Van Allen, CG Drake, JP Allison, S Hu-Lieskovan American Society of Clinical Oncology Educational Book 39, 147-164, 2019 | 585 | 2019 |
| Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44 AL Cummings, J Gukasyan, HY Lu, T Grogan, G Sunga, CM Fares, ... Nature cancer 1 (12), 1167-1175, 2020 | 25 | 2020 |
| Low concordance of patient-reported outcomes with clinical and clinical trial documentation CM Fares, TJ Williamson, MK Theisen, A Cummings, K Bornazyan, ... JCO clinical cancer informatics 2, 1-12, 2018 | 20 | 2018 |
| Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors CD Chin, CM Fares, M Campos, HW Chen, IP Shintaku, GE Konecny, ... Modern Pathology 33 (10), 2001-2010, 2020 | 15 | 2020 |
| Biomarkers that may predict response to immunotherapy in ovarian malignancies CD Chin, CM Fares, GE Konecny, J Rao Current Opinion in Obstetrics and Gynecology 32 (1), 84-90, 2020 | 9 | 2020 |
| Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC N Zhou, MA Velez, B Bachrach, J Gukasyan, CM Fares, AL Cummings, ... Lung Cancer 161, 34-41, 2021 | 8 | 2021 |
| Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report CY Chen, CM Fares, DS Shin Journal of medical case reports 15 (1), 216, 2021 | 6 | 2021 |
| Hu-Lieskovan S Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients CM Fares, EM Van Allen, CG Drake, JP Allison Am Soc Clin Oncol Educ Book 39, 147-64, 2019 | 6 | 2019 |
| Homologous recombination deficiency and molecular subtype are associated with immunogenicity in ovarian cancer CM Fares, KE Fenerty, C Chander, MK Theisen, GE Konecny Biomarkers in Medicine 16 (10), 771-782, 2022 | 2 | 2022 |
| 146 HLA-B44 motif neoepitope is associated with an anti-tumor immune microenvironment and predicts response to immune checkpoint blockade in non-small cell lung cancer R Li, C Fares, T Zhang, T Grogan, M Velez, G Ayzenberg, Y Radwan, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| HLA-B44 motif neoepitope is associated with a favorable tumor immune microenvironment and predicts ICB response in NSCLC R Li, CM Fares, TR Grogan, T Zhang, D Li, M Theisen, MA Velez, ... Cancer Research 83 (7_Supplement), 4340-4340, 2023 | | 2023 |
| Association of homologous recombination deficiency in ovarian cancer with neoantigen load and expression of immune checkpoints. K Fenerty, CM Fares, GE Konecny Journal of Clinical Oncology 39 (15_suppl), 5536-5536, 2021 | | 2021 |
| Association between immune gene signatures and neoepitopes with electrostatic charge opposite to their HLA-B binding pocket in melanoma (MEL) and lung adenocarcinoma (LUAD) CM Fares, AL Cummings, MK Theisen, N Hornstein, J Gukasyan, ... Cancer Research 80 (16_Supplement), 6614-6614, 2020 | | 2020 |
| Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism. CM Fares, AL Cummings, MK Theisen, J Gukasyan, JP Lind-Lebuffe, ... Journal of Clinical Oncology 38 (15_suppl), 3083-3083, 2020 | | 2020 |
| High-Grade Undifferentiated Sarcoma Presenting as Duodenal Mass CW Chung, CM Fares, ME Lazarus Proceedings of UCLA Healthcare 21, 2017 | | 2017 |
Eliezer Van AllenDana-Farber Cancer Institute在 dfci.harvard.edu 的电子邮件经过验证
